Tag: FDA BIMO

Right-First-Time IND Cover Letters & Cross-References (US-First)

Posted on digi By digi

Right-First-Time IND Cover Letters & Cross-References (US-First) Right-First-Time IND Cover Letters and Cross-Reference Strategy: A US-First, Inspection-Ready Playbook Why the IND cover letter is your speed lever—and how to write one that gets triaged fast Start with decisions, not descriptions The best IND cover letters are not courtesies; they are decision memos disguised as letters….

Read More “Right-First-Time IND Cover Letters & Cross-References (US-First)” »

US Regulatory Submissions

Investigator Meeting Content Map: Drive Screen Quality Day-1

Posted on digi By digi

Investigator Meeting Content Map: Drive Screen Quality Day-1 Investigator Meeting Content Map to Drive Day-1 Screening Quality (and Keep It Inspection-Ready) What an Investigator Meeting must deliver: reproducible screen quality from the very first patient The outcome we’re buying with an IM The point of an Investigator Meeting (IM) is not inspiration—it is repeatable performance….

Read More “Investigator Meeting Content Map: Drive Screen Quality Day-1” »

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

Patient Materials That Convert: Plain-Language, Consent, Burden

Posted on digi By digi

Patient Materials That Convert: Plain-Language, Consent, Burden Patient Materials That Convert: Turning Plain-Language Consent and Burden Transparency into Real Enrollment Why conversion-ready patient materials decide enrollment velocity—and how to make them inspection-proof Define “conversion” the regulator-friendly way Recruitment collateral isn’t successful because it’s beautiful; it’s successful when it predicts informed consent and sustained participation. In…

Read More “Patient Materials That Convert: Plain-Language, Consent, Burden” »

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

IDE vs IND: Device vs Drug Pathways—How US Sponsors Decide

Posted on digi By digi

IDE vs IND: Device vs Drug Pathways—How US Sponsors Decide IDE vs IND in the US: A Practical, Inspection-Ready Playbook for Choosing Between Device and Drug Pathways Outcome-oriented framing: how to pick the right pathway without losing months Start with the clinical objective and primary mode of action (PMOA) The fastest route to first-patient-in is…

Read More “IDE vs IND: Device vs Drug Pathways—How US Sponsors Decide” »

US Regulatory Submissions

Country Mix Optimization: Add Sites with Predictable Gains

Posted on digi By digi

Country Mix Optimization: Add Sites with Predictable Gains Country Mix Optimization: How to Add Sites That Deliver Predictable Gains (Not Just More Complexity) Outcome-first site expansion: when adding countries lifts velocity—and when it only adds noise The real question: will a new country raise weekly randomizations with confidence? “Add more sites” is a reflex; “add…

Read More “Country Mix Optimization: Add Sites with Predictable Gains” »

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

FDA BIMO Expectations: Inspection Readiness from Day 0

Posted on digi By digi

FDA BIMO Expectations: Inspection Readiness from Day 0 Building Day-0 Inspection Readiness: Meeting FDA BIMO Expectations with Evidence, Control, and Operational Rhythm What “Day-0 inspection readiness” really means—and why it accelerates US programs Define the goal in operational terms “Day-0 inspection readiness” means that if an investigator appeared today, the study’s conduct and records would…

Read More “FDA BIMO Expectations: Inspection Readiness from Day 0” »

US Regulatory Submissions

Pre-Submission Briefing Book: Structure, Evidence & Reviewer-Friendly Writing

Posted on digi By digi

Pre-Submission Briefing Book: Structure, Evidence & Reviewer-Friendly Writing How to Build the Pre-Submission Briefing Book: Structure, Evidence, and Writing that Makes Reviewers Say “Yes” Outcome-Oriented Briefing Books: Design for Decisions, Not Description Start with the decision, then backfill the evidence The most effective pre-submission briefing books begin with what you want the Agency to decide…

Read More “Pre-Submission Briefing Book: Structure, Evidence & Reviewer-Friendly Writing” »

US Regulatory Submissions

Clinical Protocol in INDs: Risk, Endpoints & Amendment Strategy

Posted on digi By digi

Clinical Protocol in INDs: Risk, Endpoints & Amendment Strategy Designing the Clinical Protocol for an IND: Risk Controls, Endpoints That Stand Up to Review, and a Smart Amendment Strategy Why the IND protocol is your single most leveraged document—and how to make it decision-ready Anchor to patient protection and decision utility The clinical protocol submitted…

Read More “Clinical Protocol in INDs: Risk, Endpoints & Amendment Strategy” »

US Regulatory Submissions

Cut Delays: Prior Authorization, Imaging, Scheduling Bottlenecks

Posted on digi By digi

Cut Delays: Prior Authorization, Imaging, Scheduling Bottlenecks Cut Delays Fast: How to Tame Prior Authorization, Imaging Queues, and Scheduling Bottlenecks Without Losing Compliance Why cycle-time kills enrollment—and the exact levers that buy back weeks in US/UK/EU programs The three hidden clocks that decide whether you randomize on time Across high-enrolling studies, cycle-time failures track back…

Read More “Cut Delays: Prior Authorization, Imaging, Scheduling Bottlenecks” »

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

CMC for INDs: Quality Module Essentials for Early-Phase Programs

Posted on digi By digi

CMC for INDs: Quality Module Essentials for Early-Phase Programs CMC for INDs: Building an Early-Phase Quality Module That FDA Accepts and Sites Can Execute Why CMC drives first-patient-in: the early-phase essentials and how to show them Outcome focus: fitness-for-purpose over perfection For an initial Investigational New Drug application, Chemistry, Manufacturing and Controls (CMC) is about…

Read More “CMC for INDs: Quality Module Essentials for Early-Phase Programs” »

US Regulatory Submissions